SCHEMBL3301650

SCHEMBL3301650

FC(F)(F)c1cc(NC(=S)NCc2ccc(Cl)cc2Cl)cc(C(F)(F)F)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.66
ALDH1A1 P00352 7/20 0.66
ALOX12 P18054 4/20 0.66
PPARG P37231 1/20 0.66
NCOA3 Q9Y6Q9 1/20 0.66
MYC P01106 1/20 0.59
MAX P61244 1/20 0.59
MEN1 O00255 10/20 0.58
KMT2A Q03164 10/20 0.58
LMNA P02545 10/20 0.58
HTT P42858 6/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
NPSR1 Q6W5P4 2/20 0.56
QPCT Q16769 1/20 0.53
CYP1A2 P05177 3/20 0.51
CYP3A4 P08684 3/20 0.51
CYP2D6 P10635 3/20 0.51
CYP2C19 P33261 3/20 0.51
POLB P06746 1/20 0.51
CYP2C9 P11712 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3300407 0.88 ALDH1A1 (0.54) MAPTALDH1A1ALOX12PPARGNCOA3
SCHEMBL3304422 0.86 MYC (0.67) MAPTALDH1A1ALOX12PPARGNCOA3
SCHEMBL8164838 0.86 LMNA (0.57) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL3300939 0.83 MAPT (0.79) MAPTALDH1A1ALOX12MYCMAX
SCHEMBL3305997 0.80 MYC (0.74) MAPTALDH1A1ALOX12MYCMAX
SCHEMBL3302805 0.78 MYC (0.67) MAPTALDH1A1ALOX12MYCMAX
SCHEMBL4555022 0.76 MAPT (0.67) MAPTALDH1A1MYCMAXMEN1
SCHEMBL3297435 0.75 MAPT (0.64) MAPTALDH1A1ALOX12MYCMAX
SCHEMBL2161427 0.74 MYC (0.61) MAPTALDH1A1MYCMAXMEN1
SCHEMBL3299625 0.74 MYC (1.00) MAPTALDH1A1ALOX12MYCMAX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093864-A1 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2010-04-15 US disclosed
US-20100093864-A1 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2010-04-15 US disclosed
US-20100093864-A1 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2010-04-15 US disclosed
EP-2074085-A2 ANTI-INFECTIVE THIOUREA COMPOUNDS Lica Pharmaceuticals A/S (DK) 2009-07-01 EP disclosed
WO-2008043840-A2 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2008-04-17 WO disclosed
WO-2008043840-A2 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093864-A1 ANTI-INFECTIVE THIOUREA COMPOUNDS TST, TPX2, TPMT MAPT 4691/4885ALDH1A1 4109/4885ALOX12 2250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.